172 related articles for article (PubMed ID: 28664226)
1. Eribulin shows high concentration and long retention in xenograft tumor tissues.
Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
[TBL] [Abstract][Full Text] [Related]
2. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
3. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1634-8. PubMed ID: 21324692
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
Ito K; Hamamichi S; Abe T; Akagi T; Shirota H; Kawano S; Asano M; Asano O; Yokoi A; Matsui J; Umeda IO; Fujii H
Cancer Sci; 2017 Nov; 108(11):2273-2280. PubMed ID: 28869796
[TBL] [Abstract][Full Text] [Related]
7. Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model.
Taguchi E; Horiuchi K; Senoo A; Susa M; Inoue M; Ishizaka T; Rikitake H; Matsuhashi Y; Chiba K
Biochem Biophys Res Commun; 2021 Sep; 570():89-95. PubMed ID: 34274851
[TBL] [Abstract][Full Text] [Related]
8. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
Takahashi M; Miki S; Fujimoto K; Fukuoka K; Matsushita Y; Maida Y; Yasukawa M; Hayashi M; Shinkyo R; Kikuchi K; Mukasa A; Nishikawa R; Tamura K; Narita Y; Hamada A; Masutomi K; Ichimura K
Cancer Sci; 2019 Jul; 110(7):2247-2257. PubMed ID: 31099446
[TBL] [Abstract][Full Text] [Related]
9. Eribulin mesylate in patients with refractory cancers: a Phase I study.
Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
[TBL] [Abstract][Full Text] [Related]
10. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
11. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Towle MJ; Salvato KA; Wels BF; Aalfs KK; Zheng W; Seletsky BM; Zhu X; Lewis BM; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2011 Jan; 71(2):496-505. PubMed ID: 21127197
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
[TBL] [Abstract][Full Text] [Related]
13. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
14. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
[TBL] [Abstract][Full Text] [Related]
15. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
Laughney AM; Kim E; Sprachman MM; Miller MA; Kohler RH; Yang KS; Orth JD; Mitchison TJ; Weissleder R
Sci Transl Med; 2014 Nov; 6(261):261ra152. PubMed ID: 25378644
[TBL] [Abstract][Full Text] [Related]
16. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S; Asano M; Adachi Y; Matsui J
Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.
Yu Y; Desjardins C; Saxton P; Lai G; Schuck E; Wong YN
Int J Pharm; 2013 Feb; 443(1-2):9-16. PubMed ID: 23313921
[TBL] [Abstract][Full Text] [Related]
18. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
Narayan S; Carlson EM; Cheng H; Du H; Hu Y; Jiang Y; Lewis BM; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1630-3. PubMed ID: 21324686
[TBL] [Abstract][Full Text] [Related]
19. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
[No Abstract] [Full Text] [Related]
20. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.
Miki S; Imamichi S; Fujimori H; Tomiyama A; Fujimoto K; Satomi K; Matsushita Y; Matsuzaki S; Takahashi M; Ishikawa E; Yamamoto T; Matsumura A; Mukasa A; Nishikawa R; Masutomi K; Narita Y; Masutani M; Ichimura K
Cancer Sci; 2018 Jul; 109(7):2275-2285. PubMed ID: 29758120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]